glycopyrrolate inhaled
Selected indexed studies
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. (N Engl J Med, 2020) [PMID:32579807]
- Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. (Int J Chron Obstruct Pulmon Dis, 2018) [PMID:29928118]
- Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. (Lancet Respir Med, 2018) [PMID:30232048]
_Worker-drafted node — pending editorial review._
Connections
glycopyrrolate inhaled is a side effect of
Sources
- Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. (2016) pubmed
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. (2020) pubmed
- Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. (2018) pubmed
- Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. (2018) pubmed
- Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. (2021) pubmed
- Glycopyrrolate. (2006) pubmed
- Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease. (2025) pubmed
- Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. (2024) pubmed
- Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT. (2023) pubmed
- Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy. (2025) pubmed